Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

61. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial Full Text available with Trip Pro

Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial Despite the enormous success of total knee arthroplasty (TKA), chronic neuropathic pain can develop postoperatively and is both distressing and difficult to treat once established. We hypothesized that perioperative treatment with pregabalin, a chronic pain medication, would reduce the incidence of postsurgical neuropathic pain.We performed a randomized, placebo (...) -controlled, double-blind trial of pregabalin (300 mg) administered before TKA and for 14 days after TKA (150-50 mg twice daily). Patients were screened for the presence of neuropathic pain at 3 and 6 mo postoperatively using the Leeds Assessment of Neuropathic Symptoms and Signs scale. Secondary outcomes included postsurgical recovery and rehabilitation measures, including knee range of motion, opioid consumption, postoperative pain scores, sleep disturbance, and time to discharge as well

2010 EvidenceUpdates Controlled trial quality: predicted high

62. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

2010 NHS Economic Evaluation Database.

63. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial (Abstract)

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial To compare the efficacy and safety of pregabalin and amitriptyline in alleviating pain associated with diabetic peripheral neuropathy.A randomized, double-blind, crossover, active-control, clinical trial with variable dose titration was carried out (n = 51). Amitriptyline orally, at doses of 10, 25 and 50 mg at night-time and pregabalin orally, at doses of 75, 150 and 300 mg twice daily (...) , by optional titration was used. Each drug treatment was of 5 weeks. There was a placebo washout period for 3 weeks between the two drugs. Assessment for pain relief, overall improvement and adverse events were carried out.Good, moderate and mild pain relief were noted in 21 (48%), 6 (13%) and 7 (15%) patients on pregabalin and 15 (34%), 5 (11%) and 12 (27%) patients on amitriptyline, respectively, by patient's global assessment of efficacy and safety. Patient and physician's global assessment, McGill pain

2010 EvidenceUpdates Controlled trial quality: uncertain

64. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

65. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Full Text available with Trip Pro

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared oral pregabalin, an anticonvulsant medication, with venlafaxine extended release, for patients with generalised anxiety disorder. The authors concluded that pregabalin appeared to be cost

2010 NHS Economic Evaluation Database.

66. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review

Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

67. Randomised controlled trial: Pregabalin similar to lorazepam for alcohol withdrawal symptoms

Randomised controlled trial: Pregabalin similar to lorazepam for alcohol withdrawal symptoms Pregabalin similar to lorazepam for alcohol withdrawal symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin similar to lorazepam for alcohol withdrawal symptoms Article Text Therapeutics Randomised controlled trial Pregabalin similar to lorazepam for alcohol withdrawal symptoms Giovanni Addolorato 1 , Lorenzo Leggio 1 , 2

2010 Evidence-Based Medicine

68. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis

Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 NHS Economic Evaluation Database.

69. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Full Text available with Trip Pro

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of pregabalin versus placebo, duloxetine, gabapentin, tramadol, or amitriptyline, for the treatment of fibromyalgia. Pregabalin 450mg was consistently more cost-effective than pregabalin 300mg and both doses were cost-effective over placebo and duloxetine, for a population with severe disease. The study

2010 NHS Economic Evaluation Database.

70. Pregabalin - diabetic peripheral neuropathy

Pregabalin - diabetic peripheral neuropathy Common Drug Review CEDAC Meeting – July 15, 2009; CEDAC Reconsideration – September 16, 2009 Notice of CEDAC Final Recommendation – September 23, 2009 Page 1 of 5 © 2009 CADTH CEDAC FINAL RECOMMENDATION PREGABALIN RESUBMISSION (Lyrica ® – Pfizer Canada Inc.) Indication: Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that pregabalin not be listed. Reasons (...) for the Recommendation: 1. The Committee considered the results of three new randomized placebo-controlled trials of pregabalin in patients with diabetic peripheral neuropathy that met the CDR protocol since the original review. Two of the three trials did not show a statistically significant reduction in mean pain scores at study endpoint for pregabalin compared with placebo. 2. There are a number of drug classes used in the treatment of pain associated with diabetic peripheral neuropathy, including tricyclic

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

71. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

72. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials

Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

73. A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy (Abstract)

A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy Pregabalin has anticonvulsant, antihyperalgesic, and anxiolytic properties. In this study we evaluated the control of pain after perioperative administration of pregabalin 300 or 600 mg, compared with diazepam 10mg. Altogether 91 women scheduled for laparoscopic hysterectomy were randomized to receive diazepam 10mg (D10), pregabalin 150 mg (P300) or 300 mg (P600 (...) surgery was smaller in the P600 group than in the P300 group (0.09 vs. 0.16 mg kg(-1); P=0.025). The total dose of oxycodone (0-24h after surgery) was smaller in the P600 group than in the D10 group (0.34 vs. 0.45 mg kg(-1); P=0.046). The incidence of dizziness (70% vs. 35%; P=0.012), blurred vision (63% vs. 14%; P=0.002) and headache (31% vs. 7%; P=0.041) were higher in the P600 group than in the D10 group. In conclusion, perioperative administration of pregabalin 600 mg decreases oxycodone

2008 EvidenceUpdates Controlled trial quality: predicted high

74. Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Full Text available with Trip Pro

Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Article Text Therapeutics Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Statistics from Altmetric.com Request Permissions If you

2008 Evidence-Based Mental Health

75. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain

A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain Annemans L, Caekelbergh K, Morlion B, Hans G, De Cock P, Marbaix S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of pregabalin added to usual care, compared with usual care alone, for the treatment of peripheral neuropathic pain. The authors concluded that pregabalin led to a small, but significant, improvement in patient health without increasing costs from the perspective of the Belgian health care payer. In general, the quality

2008 NHS Economic Evaluation Database.

76. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Full Text available with Trip Pro

Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Vera-Llonch M, Brandenburg N A, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of pregabalin as an additional therapy in comparison with usual care in patients with refractory partial epilepsy. The authors concluded that the cost-effectiveness of pregabalin compared favourably with the published estimates of the cost-effectiveness of other add-on antiepileptic drugs. The study

2008 NHS Economic Evaluation Database.

77. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Liedgens H (...) and pregabalin for the treatment of patients with post-herpetic neuralgia. The authors concluded that the lidocaine plaster was the most cost-effective treatment. The methodology had several limitations, so the authors' conclusions should be treated with caution. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective The aim was to assess the cost-effectiveness of four options for the treatment of post-herpetic neuralgia in patients who did not experience pain relief

2008 NHS Economic Evaluation Database.

78. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia

Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

79. pregabalin

pregabalin CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION PREGABALIN (Lyrica - Pfizer Canada Inc.) Description: Pregabalin is approved for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Dosage Forms: 25 mg, 50 mg, 75 mg, 150 mg and 300 mg capsules Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that pregabalin not be listed. Reasons for the Recommendation: 1 (...) . The Committee considered the results of 12 randomized controlled trials (RCTs), 6 in painful DPN, 5 in PHN and 1 in a mixed painful DPN and PHN population. With the exception of 1 RCT in painful DPN that included amitriptyline as a comparator, all trials were placebo controlled and of relatively short duration ( =13 weeks). The lack of RCTs comparing pregabalin to other therapies makes it very difficult to determine the relative efficacy and safety of pregabalin. 2. Compared to placebo, pregabalin produced

2006 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

80. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective

Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian (...) ) and postherpetic neuralgia (PHN). The treatments were gabapentin (between 900 and 3,600 mg/day) and pregabalin (between 150 and 600 mg/day). In particular, the analysis focused, in the base-case, on a dosage of 2,400 mg for gabapentin and 430 mg for pregabalin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population comprised two hypothetical cohorts, one of patients with DPN and one of patients with PHN. Only patients

2006 NHS Economic Evaluation Database.